Cilaril is primarily used for the long-term, continuous management of essential hypertension (chronic high blood pressure). This fixed-dose combination may be considered relevant for adult patients who require dual-agent management. The therapy is applied in situations where additional supportive management is needed beyond a single agent, addressing the persistent, elevated pressure that creates noticeable physiological strain on the vascular system.

The core therapeutic areas include managing essential hypertension and contributing to the long-term risk management of cardiovascular events. By generally controlling high blood pressure, the medication may assist with easing the systemic load on vital organs. This action plays a role in supporting the management of risks linked to chronic high blood pressure, contributing to the management of complications, such as stroke or heart attack.

“The use of a combination therapy generally assists with managing blood pressure control in relevant patient groups.”

For patients who are stabilized on the individual components, the single tablet may help support more steady compliance with the therapeutic plan. This assists with maintaining functional stability by easing the complexity of the treatment regimen.

Quick Fact: Support for Persistent Vascular Strain

Cilaril (an ACE inhibitor) has specific eligibility requirements and absolute contraindications defined by regulatory labeling that determine who may or may not use the medicine.

Populations for Whom Use is Contraindicated

Cilaril is prohibited for patients with a history of angioedema (swelling of the face, tongue, or throat) related to previous ACE inhibitor treatment, or a history of hereditary or idiopathic angioedema. It is also contraindicated in patients with diabetes who are taking a medicine containing aliskiren, or for any patient taking a neprilysin (NEP) inhibitor (e.g., sacubitril).

Age and Pregnancy Eligibility

Category	Official Regulatory Status
Pregnancy	Contraindicated in the second and third trimesters; must be discontinued immediately upon detection of pregnancy due to risk of fetal injury and death.
Pediatric Patients	Safety and effectiveness have not been established in children younger than 6 years of age.

Use-Limiting Conditions

Use requires special consideration and caution in populations with impaired renal function (kidney disease, generally defined as GFR le 30 mL/min/1.73 m^2) or hepatic failure (liver problems). These conditions may necessitate close monitoring and dose adjustment as detailed in official prescribing information.

Interactions with other medicines and products

This section outlines interactions with other substances as documented in official government regulatory information for Cilazapril/Hydrochlorothiazide (Cilaril).

---

Formal Interaction Restrictions

Co-administration with Sacubitril/Valsartan is formally contraindicated due to the risk of angioedema. A mandatory 36-hour separation period must be observed when transitioning to or from a drug containing a neprilysin inhibitor. The combination with Aliskiren-containing drugs is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR < 60 mL/min).

---

Pharmacodynamic and Exposure-Altering Interactions

Several agents are officially documented to affect the drug's activity or concentration:

• Lithium: The diuretic component reduces the renal clearance of Lithium, creating a high risk of lithium toxicity.
• Agents affecting potassium: Co-administration with potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes increases the risk of hyperkalemia.
• NSAIDs: Non-steroidal anti-inflammatory drugs may reduce the blood pressure-lowering effect and increase the risk of renal function deterioration.
• mTOR and DPP-IV Inhibitors: Agents like Sirolimus and Vildagliptin increase the risk of angioedema when combined with the ACE inhibitor component.
• Cholestyramine and Colestipol: These anionic exchange resins significantly reduce the absorption of the Hydrochlorothiazide component. They must be administered at least 4 hours before or 4 to 6 hours after Cilaril.
• Alcohol: May potentiate the risk of orthostatic hypotension.

Primary Intracellular Targets

Cilaril functions as a selective allosteric modulator of the enzyme Farnesyl Pyrophosphate Synthase ( FPPS), a key component of the mevalonate pathway. Cilaril engages a regulatory site distinct from the active catalytic domain, inducing a conformational change that reduces the enzyme's affinity for its natural substrates, dimethylallyl pyrophosphate ( DMAPP) and isopentenyl pyrophosphate ( IPP).

Modulation and Consequence

This functional inhibition of FPPS disrupts the biosynthesis of farnesyl pyrophosphate ( FPP) and geranylgeranyl pyrophosphate ( GGPP). These pyrophosphate lipids are necessary intermediates for the post-translational modification of small signaling GTPases (e.g., Rho, Rac, and Rab families) via prenylation. The resulting impairment of GTPase prenylation prevents their essential membrane localization and activation. This attenuation of GTPase signaling ultimately diminishes downstream cellular activities, including cytoskeletal rearrangement and cell adhesion, leading to a system-level physiological consequence of reduced cellular migration and altered immune cell function.

How to Use Cilaril

Cilaril is a fixed-dose combination medicine containing Cilazapril and Hydrochlorothiazide, and its usage follows established clinical parameters to ensure appropriate administration.

---

Official Administration Protocol

Feature	Instruction
Route of Administration	The medicine is taken orally as a film-coated tablet.
Standard Adult Dose	The standard regimen is one tablet (e.g., 5 mg/12.5 mg strength) taken once daily.
Timing & Frequency	The tablet must be taken once a day at approximately the same time, preferably in the morning.
Food Relationship	Administration is permitted with or without food, as food intake has no clinically significant effect on absorption.

---

Procedural and Population Constraints

The fixed-dose combination tablet must be swallowed whole with water and is not to be chewed or crushed. Cilaril is intended for long-term, continuous management of essential hypertension and is typically employed as replacement therapy after individual component doses have been established; it is not indicated for initial therapy.

Standard parameters specify that Cilaril is not recommended for use in children and adolescents under 18 years of age due to lack of established safety data. Furthermore, the combination is not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min), and careful dose adaptation is required for older adults.

This protocol ensures the medicine is used in a standardized manner, adhering to the prescribed administration parameters.

Research Evidence / Overview of Studies for Cilaril

Evidence for use in Essential Hypertension

Cilaril, the combination of Cilazapril and Hydrochlorothiazide, was studied for the long-term management of high blood pressure (essential hypertension) in adults. The research base includes randomized controlled trials (RCTs). These studies typically use a design where participants are randomly assigned to one of several groups, which may include the combination medicine, one of the components alone, or a placebo (an inactive pill). This research structure was applied in studies examining outcomes related to physiological strain or stress linked to elevated blood pressure.

Research examined the combination primarily in adult patients with mild to moderate essential hypertension. Studies focused on patients whose blood pressure levels met specific criteria for requiring additional management beyond monotherapy (a single agent). Trials monitored short-term changes over intervals typically lasting four to eight weeks. The findings describe patterns observed in the studies where research examined the measured changes in trough and peak blood pressure markers for the combination group and compared these to the measured changes in the monotherapy groups. The research also described the percentage of participants whose measured blood pressure values aligned with pre-defined study endpoints.

---

Long-term Studies and Maintenance of Effect

Research has explored whether the short-term symptom changes observed in initial trials can be sustained over longer periods. When considering the research on long-term outcomes, such as major events like heart attack and stroke, the evidence is limited for the specific Cilazapril/Hydrochlorothiazide combination itself. The specific research regarding the combination's impact on long-term health outcomes, such as major cardiovascular events, is largely inferred from established data on the component drug classes rather than being the result of its own dedicated, long-term outcomes trials. This means the observed long-term patterns may be extrapolated from the data available for the component medications.

---

Summary of Evidence Limitations and Remaining Uncertainty

Data for certain patient groups remain insufficient. For example, the safety and effectiveness of this fixed combination are not fully established in children. Similarly, the research base is limited for patients with certain complex, pre-existing heart or kidney conditions. Furthermore, comparative evidence is lacking to definitively describe its performance against every other available fixed-dose combination for hypertension. Research provides context but not individual predictions about how Cilaril may be used, as study results reflect the specific conditions under which they were conducted.

Key Studies & References WHO Model List of Essential Medicines: Fixed-dose combinations of cardiovascular medicines – prevention of atherosclerotic cardiovascular diseases

Official Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of Cilaril (Cilazapril/Hydrochlorothiazide) oral tablets to maintain stability.

Storage Domain	Required Condition
Temperature	Store at Controlled Room Temperature, not exceeding mathbf25degree C or mathbf30degree C.
Protection	Keep in the original container and outer carton to protect from moisture and light.
Stability	Do not use the medicine after the labeled expiry date stated on the package.
Child Safety	Mandatory instruction to keep this medicine out of the sight and reach of children.

For disposal, unused or expired Cilaril tablets must not be thrown away via household waste or wastewater. Disposal must be carried out in accordance with local environmental regulations and pharmaceutical waste requirements.